Two recently approved leukemia drugs could be enlisted against treatment-resistant lung cancer, with a clinical trial expected to launch in Toronto and Zagreb, Croatia, later this year to evaluate one of them.
Feb 24, 2020
0
122
Researchers at Kanazawa University report in the Journal of Thoracic Oncology a promising novel approach for a combined treatment of the most common type of lung cancer and associated secondary cancers in the central nervous ...
Feb 7, 2020
0
1
A new study led by researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) shows how resistance to a promising targeted ...
Jan 14, 2020
0
18
Targeted, highly effective cancer treatments often produce debilitating side effects. This is the case with one commonly used therapy which works by blocking the epidermal growth factor receptor (EGFR), a protein that stimulates ...
Dec 12, 2019
0
68
Using CRISPR/Cas9 knockout screens a multi-institutional research team systematically interrogated the essentiality of more than 10,000 forkhead box protein A1 (FOXA1) and CTCF binding sites in breast and prostate cancer ...
Nov 11, 2019
0
11
A team of researchers affiliated with a large number of institutions in the U.S. has found that a subgroup of breast cancers have two PIK3CA mutations, and that such mutations occur on the same allele. In their paper published ...
Most cases of gastrointestinal stromal tumor (GIST), a type of soft-tissue cancer (sarcoma), are caused by mutations in genes that can be effectively targeted with drugs that inhibit the activity of rogue cancer-promoting ...
Oct 16, 2019
0
59
No matter the pathogen—virus, bacterium or fungus—many "pick a specific type of lock" on the surface of cells, which allows the microbe to break and enter into the inner sanctum of the host's genome.
The relationship between gene alterations and response to anti-PD-L1 with and without anti-CTLA-4 are not well characterized. Dr. N. Rizvi from Columbia University Medical Center in New York today presented an update from ...
Sep 9, 2019
0
0
Since its approval in April 2019, dacomitinib has been available for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor ...
Aug 19, 2019
0
3
